Víctor Moreno

14.0k total citations · 2 hit papers
287 papers, 5.5k citations indexed

About

Víctor Moreno is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Víctor Moreno has authored 287 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Oncology, 96 papers in Pulmonary and Respiratory Medicine and 71 papers in Molecular Biology. Recurrent topics in Víctor Moreno's work include Cancer Immunotherapy and Biomarkers (66 papers), Lung Cancer Treatments and Mutations (49 papers) and CAR-T cell therapy research (40 papers). Víctor Moreno is often cited by papers focused on Cancer Immunotherapy and Biomarkers (66 papers), Lung Cancer Treatments and Mutations (49 papers) and CAR-T cell therapy research (40 papers). Víctor Moreno collaborates with scholars based in Spain, United States and France. Víctor Moreno's co-authors include Emiliano Calvo, Valentina Boni, Josep Tabernero, Filippo de Braud, Stan B. Kaye, Johann S. de Bono, Udai Banerji, Marta Gil-Martín, Sylvie Rottey and Christine L. Hann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Víctor Moreno

273 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Fiona Thistlethwaite, Víctor Moreno et al. profile →
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

2020 237 citations Víctor Moreno et al. profile →

Peers

Countries citing papers authored by Víctor Moreno

Since Specialization

Citations

This map shows the geographic impact of Víctor Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Víctor Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Víctor Moreno more than expected).

Fields of papers citing papers by Víctor Moreno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Víctor Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Víctor Moreno. The network helps show where Víctor Moreno may publish in the future.

Co-authorship network of co-authors of Víctor Moreno

This figure shows the co-authorship network connecting the top 25 collaborators of Víctor Moreno. A scholar is included among the top collaborators of Víctor Moreno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Víctor Moreno. Víctor Moreno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies 2024 ·Clinical Cancer Research ·Jason J. Luke, Karen A. Gelmon, Lillian L. Siu, Víctor Moreno, Jayesh Desai, Carlos Gomez‐Roca, Matteo S. Carlino, Russell K. Pachynski, Rasha Cosman, Quincy S. Chu, Silvia Damian, Giuseppe Curigliano, (unknown), (unknown), Chandrika Jeyamohan, (unknown), Li Zhu, Julia Santucci-Pereira, Danielle Greenawalt, Josep Tabernero	8
2	151P Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients 2024 ·Annals of Oncology ·(unknown), Tamara Tanos, Christian Heichinger, (unknown), (unknown), (unknown), Catriona Ooi, Vaios Karanikas, Michael A. Cannarile, (unknown), (unknown), Víctor Moreno, (unknown), Tae‐Woo Kim, (unknown), (unknown), (unknown), (unknown), Fiona Thistlethwaite, Victoria K. Woodcock	0
3	61MO Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS) 2024 ·ESMO Open ·Peter Reichardt, Patrick Schöffski, Patricia LoRusso, Noboru Yamamoto, Víctor Moreno, (unknown), Ulrich M. Lauer, Neeta Somaiah, Chang‐Ping Hu, (unknown), (unknown), Mrinal M. Gounder	1
4	160TiP A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab 2024 ·Annals of Oncology ·María Vieito, (unknown), (unknown), Ezra Y. Rosen, Jordi Rodón, Víctor Moreno, Valentina Gambardella, (unknown), Sophie Cousin, Philippe A. Cassier, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Riadh Lobbardi, Eunju Hurh, Elizabeth I. Buchbinder	0
5	161P Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment 2024 ·Annals of Oncology ·(unknown), Bernardo Sgarbi Reis, (unknown), (unknown), Daniel J. Lee, (unknown), (unknown), Stefan N. Symeonides, (unknown), Antoine Hollebecque, Natascha Rieder, (unknown), Solveig Badillo, (unknown), (unknown), Corinne Rusterholz, (unknown), (unknown), Víctor Moreno, Angela Epp	2
6	Understanding the Preclinical Efficacy of Antibody–Drug Conjugates 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), Emiliano Calvo, Víctor Moreno, Francisco Morís, Pedro Pérez‐Segura, Balázs Győrffy, Atanasio Pandiella, Alberto Ocaña	2
7	1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors 2024 ·Annals of Oncology ·M. De Miguel, (unknown), Víctor Moreno, (unknown), Jessica Menis, Giuseppe Daniele, Anthony B. El-Khoueiry, Alexander I. Spira, Alessia Gravina, Anthony J. Olszanski, (unknown), (unknown), (unknown), (unknown), (unknown), William D. Hedrich, (unknown), Jinping Gan, Xiaorong Shi, Robert H.I. Andtbacka	0
8	612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors 2024 ·Annals of Oncology ·María Vieito, (unknown), (unknown), Ezra Y. Rosen, Jordi Rodón, Víctor Moreno, Valentina Gambardella, (unknown), Sophie Cousin, Philippe A. Cassier, (unknown), (unknown), (unknown), (unknown), (unknown), Riadh Lobbardi, Hao Liu, Eunju Hurh, Leonard Reyno, Elizabeth I. Buchbinder	3
9	Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned 2023 ·Journal of Hematology & Oncology ·(unknown), (unknown), (unknown), Cristina Nieto‐Jiménez, (unknown), (unknown), Emiliano Calvo, Pedro Pérez‐Segura, Víctor Moreno, Francisco Morís, Alberto Ocaña	26
10	Considerations for the clinical development of immuno-oncology agents in cancer 2023 ·Frontiers in Immunology ·Atanasio Pandiella, Emiliano Calvo, Víctor Moreno, Eitan Amir, Arnoud J. Templeton, Alberto Ocaña	2
11	500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study 2023 ·Annals of Oncology ·María Vieito, Juan Manuel Sepúlveda-Sánchez, Víctor Moreno, Giuseppe Lombardi, Agostina Stradella, Rikke Hedegaard Dahlrot, Charlotte Aaquist Haslund, Marjolein Geurts, Estela Pineda, Petter Brandal, Filip De Vos, María Ángeles Vaz Salgado, Maria Martinez‐García, Marina Macchini, (unknown), Teresa Sánchez, Bishoy Hanna, (unknown), Zariana Nikolova, Matteo Simonelli	2
12	RTID-03. A PHASE 1/2 STUDY OF THE WEE1 INHIBITOR DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE +- RADIOTHERAPY IN ADULTS WITH RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA 2023 ·Neuro-Oncology ·Patrick Roth, Kyriakos P. Papadopoulos, María Vieito, Jonathan T. Yang, Nazanin Majd, Juan Manuel Sepúlveda-Sánchez, Lauren Schaff, Víctor Moreno, (unknown), Sandrine Micallef, Anne Bellon, (unknown), (unknown), (unknown), Víctor Rodríguez-Freixinós, Jordi Rodón	1
13	Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I Trial 2023 ·International Journal of Radiation OncologyBiologyPhysics ·C. Le Tourneau, Zoltán Takácsi‐Nagy, Laetitia Finzi, X. Liem, Valentin Calugaru, Víctor Moreno, Emiliano Calvo, Sébastien Salas, Bernard Doger, (unknown), X. Mirabel, Nathalie Badois, A. Chillès, Nicolas Fakhry, (unknown), (unknown), (unknown), (unknown), (unknown), Maria Lesnik	1
14	362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC) 2023 ·Annals of Oncology ·Paolo Bossi, (unknown), Irene Braña, Víctor Moreno, Valentina Boni, Philippe Jamme, Justin Call, Chunhong Yan, (unknown), (unknown), Andrew K. Joe, (unknown), Amaury Daste	5
15	2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer 2022 ·International Journal of Gynecological Cancer ·Kathleen N. Moore, Adam Asch, Víctor Moreno, Emiliano Calvo, Marcus O. Butler, Jon Zugazagoitia, David S. Hong, Ahmed M. Galal, (unknown), Maria J. de Miguel, Quan Lin, (unknown), (unknown), (unknown), (unknown), Revashnee Naidoo, Natalie Bath, (unknown), Elliot Norry, Jeffrey Clarke	1
16	200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results 2022 ·Immuno-Oncology Technology ·Matteo Simonelli, (unknown), (unknown), (unknown), (unknown), Víctor Moreno, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
17	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody 2021 ·Clinical Cancer Research ·James J. Harding, Víctor Moreno, Yung‐Jue Bang, Min Hee Hong, Amita Patnaik, José Trigo, Anna M. Szpurka, Noboru Yamamoto, Toshihiko Doi, Siqing Fu, Boris Calderón, Nieves Vélez de Mendizábal, Emiliano Calvo, Danni Yu, Leena Gandhi, (unknown), Violeta Régnier Galvão, Ching Ching Leow, Maria J. de Miguel	116
18	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors 2019 ·Clinical Cancer Research ·Rastislav Bahleda, Antoîne Italiano, Cinta Hierro, Alain C. Mita, Andrés Cervantes, Nancy Chan, Mark M. Awad, Emiliano Calvo, Víctor Moreno, Ramaswamy Govindan, Alexander I. Spira, (unknown), Bob Zhong, (unknown), Italo Poggesi, Trilok Parekh, Hong Xie, Jeffrey R. Infante, Josep Tabernero	187
19	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study 2014 ·Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, (unknown), Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	14
20	A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer 2011 ·Clinical Cancer Research ·E. Casado, Víctor Moreno, José Javier Sánchez, Montserrat Blanco, Joan Maurel, Jaime Feliú, Carlos Fernández-Martos, Javier de Castro, Beatriz Castelo, Cristóbal Belda-Iniesta, María Sereno, (unknown), Emilio Burgos, Miguel Ángel García‐Cabezas, Noemí Manceñido, Rosa Miquel, Damián García‐Olmo, Manuel González-Barón, Paloma Cejas	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact